Rocuronium Injection Research Articles

The Pharmaceutical Composition of Rocuronium Bromide May Promote Catecholamine Release From PC-12 Cells.

Several cases of pheochromocytoma presenting with hypertensive crises after anesthesia induction, possibly caused by rocuronium injection, have been reported. Rocuronium has two compositions: rocuronium bromide (RB) in sodium acetate hydrate/acetic acid buffer solution (acetic acid vehicle)and RB in glycine/hydrochloric acid buffer solution (hydrochloric acid vehicle). This study assessed the effect of rocuronium composition on the release of catecholamine from PC-12 rat adrenal pheochromocytoma cells. PC-12 cells (3x105 cells) were cultured for 96 hours, then 1 mL of reagent was added for five minutes. First, the experiment used phosphate-buffered saline (PBS (-)), RB in PBS (-), an acetic acid vehicle, and RB in the acetic acid-based vehicle. Next, the experiment used an acetic acid vehicle and a hydrochloric acid vehicle. Then the experiment used an acetic acid vehicle and a mixed solution of 0.2 mL acetic acid vehicle + 0.8 mL normal saline (NS). Cell supernatants were collected and norepinephrine (NE) and dopamine (DA) concentrations were measured using high-performance liquid chromatography. Release of NE and DA was caused by acetic acid vehicle, not by RB in PBS (-). Hydrochloric acid vehicles similarly showed a significantly lower release of NE and DA than acetic vehicle acid (NE, P=0.002; DA, P=0.002). In addition, the acetic acid vehicle diluted 5-fold with NS showed a significantly lower release of NE and DA than the acetic acid vehicle alone (NE, P=0.005; DA, P=0.002). The concentration of acetic acid in the buffer solution, not RB, caused the release of catecholamines from PC-12 cells.

Analysis of pressure-induced deviation of the cricothyroid membrane among pediatric patients

BackgroundsHypoxemia develops more quickly in children than in adults due to their high oxygen consumption relative to their body weight and small functional residual capacity. Therefore, cricothyroid puncture must be performed promptly in cannot-intubate and cannot-ventilate situations. However, the success rate of cricothyroid puncture in children is <1%. We hypothesized that the low success rate of cricothyroid puncture in children may be related to the cricothyroid membrane's hypermobility. The aim of the present study was to measure the deviation of the cricothyroid membrane from the midline when applying compressive pressure.MethodsAfter obtaining institutional ethics committee approval, written informed consent was obtained from the patients’ parents. Children aged from 1 month to 15 years who had undergone scheduled operations under general anesthesia and with an American Society of Anesthesiologists Physical Status Classification grade of 1 or 2 were enrolled in this study. The patients were divided into the following four different age groups: 1 month–1 year, 2–4 years, 5–10 years, and 11–15 years. After the intravenous injection of fentanyl, propofol, and rocuronium, the airway was identified using a linear hockey stick ultrasound probe. The cricothyroid membrane was compressed with a force of 5 newtons (N), and cricothyroid membrane deflection was recorded. The primary outcome was the cricothyroid membrane deviation from the midline relative to the tracheal diameter.ResultsTwenty patients were enrolled in this study. No adverse events were noted. The mean cricothyroid membrane deviations from the midline divided by the tracheal diameter was 0.16 ± 0.09, 0.05 ± 0.04, 0.04 ± 0.04, and 0.02 ± 0.03 in children aged 1 month–1 year, 2–4 years, 5–10 years, and 11–15 years, respectively.ConclusionThe cricothyroid membrane deviation due to the application of a compressive force to the overlying skin tended to be larger in younger patients.

Feasibility of the enhanced neuromuscular blockade recovery protocol with selective use of sugammadex in thyroid surgery with intraoperative neuromonitoring.

To investigate feasibility of utilizing enhanced neuromuscular blocking agents with selective recovery protocol during thyroid surgery with intraoperative neuromonitoring (IONM). Two-hundred and ninety patients were randomized into two groups: group A 0.3 mg/kg rocuronium and group B 0.6 mg/kg. Sugammadex 2 mg/kg was injected if needed followed initial vagal stimulation (V0). Electromyography signals from vagus and recurrent laryngeal nerves before and after resection were recorded as V1, V2, R1, and R2. In group B, 30 patients (20.7%) had V0 signals <100 μV, compared to 9 (6.2%) in group A. After sugammadex administration, 144 patients (99.3%) in both groups achieved positive V1 signals. Group B demonstrated a shorter surgical time from rocuronium injection to V2 stimulation compared to group A, accompanied by a significantly lower incidence of intraoperative body movement (0 vs. 16 patients). 0.6 mg/kg rocuronium with selective use 2 mg/kg sugammadex for IONM in thyroid surgery can meet both anesthesia and surgery demands.

The effect of orally administered metoprolol on the frequency and severity of rocuronium injection pain

Objectives: This study aimed to examine the effects of orally administered metoprolol on the frequency and severity of pain caused by rocuronium injection in patients who started to use and were currently using oral metoprolol for any reason such as ischemic heart disease, hypertension, and arrhythmias. Methods: Patients were evaluated in four groups. Group M: patients currently using metoprolol and who did not receive lidocaine before the application of rocuronium. Group ML: patients currently using metoprolol and who received lidocaine before rocuronium application. Group L: patients currently not using metoprolol and received lidocaine before rocuronium application. Group C: patients currently not using metoprolol and who did not receive lidocaine before rocuronium application. Following the induction of general anesthesia with thiopental sodium, a researcher blind to the groups observed the pain during rocuronium injection based on the following scale: (1) no reaction, (2) movement only in the ankle, (3) movement or withdrawal only in the arm (shoulder and ankle), and (4) diffuse reaction (movement or withdrawal in more than one extremity, coughing and holding breath). Results: Two hundred patients with 50 in each of four groups were included. The incidence of pain was statistically significantly lower in Group ML compared to Groups M and C (p = 0.001). The correlations between pain caused by rocuronium injection and duration of metoprolol usage and the time since the last dose were not statistically significant (for all, p &amp;gt; 0.05). Conclusions: Oral metoprolol combined with lidocaine reduced pain and withdrawal reflex caused by rocuronium injection. No significant difference was observed between the last dose and the duration of metoprolol usage.

Sugammadex for reversal of rocuronium-induced neuromuscular blockade during alfaxalone anesthesia in dogs

ObjectiveTo investigate the reversal effect of sugammadex on neuromuscular blockade induced by a single bolus of rocuronium in dogs under alfaxalone anesthesia. Study designRandomized, prospective, crossover experimental study. AnimalsA group of six adult Beagle dogs (three females and three males), weighing 11.3–15.8 kg and aged 6–8 years, were used. MethodsDogs were anesthetized twice with a 1.25 times minimum infusion rate of alfaxalone, with a washout period of at least 14 days between experiments. Neuromuscular function was monitored using acceleromyography with train-of-four (TOF) stimulation of the peroneal nerve. After recording the control TOF ratio (TOFRC), rocuronium (0.5 mg kg–1) was administered intravenously. Subsequently, sugammadex (4 mg kg–1) or an equal volume of saline (control treatment) was administered intravenously when the TOF count returned from 0 to 1 after neuromuscular blockade. Time from rocuronium injection to TOF count = 0 (onset time), time from TOF count = 0 to TOF count = 1 (maximum blockade period), time of first twitch amplitude recovery from 0.25 to 0.75 (recovery index), and time from sugammadex or saline administration to TOF ratio/TOFRC ≥ 0.9 (recovery time) were recorded. ResultsThe onset time and maximum blockade duration did not differ between sugammadex treatment [1.2 (0.7–1.5) minutes and 9.9 (6.3–10.5) minutes, respectively] and control treatment [median (range); 1.0 (0.7–1.1) minutes and 9.9 (8.8–11.5) minutes, respectively] (p = 0.219 and 0.844, respectively). Recovery index was 0.5 (0.3–0.7) minutes in sugammadex treatment, which was shorter than that in control treatment [4.5 (3.7–4.9) minutes] (p = 0.031). Recovery time was 0.8 (0.5–2.8) minutes in sugammadex treatment, which was shorter than that in control treatment [10.5 (6.8–14.3) minutes] (p = 0.031). Conclusions and clinical relevanceRocuronium-induced neuromuscular blockade was effectively reversed by sugammadex in dogs anesthetized with alfaxalone.

Effects of COX 1-2 Inhibitors on Prevention of Rocuronium Injection Pain: Controlled, Randomised, Double Blind Study

Aim: Rocuronium bromide is a painful agent during induction of general anaesthesia. The aim of the study is to investigate the effects of Cyclooxygenase (COX) inhibitors as a resque agent against the rocuronium pain.&#x0D; Material and Methods: Sixty patients of either sex scheduled for under general anesthesia were enrolled in this study. Patients were allocated into two groups (Group 1: Dexkethoprofen group, Group 2: Control group). Pain was evaluated by during rocuronium injection, patients were scored by a scale showed below. 0; No movement response to injection, 1; Mild movement response to injection, 2; Hand withdrawal response to injection, 3; Arm withdrawal response to injection. We also evaluated the pain with 2 questions when the patient was in the recovery room. Question 1. What was the last feeling before you fall into sleep? and question 2. Did you feel any pain on your hand during medication injection for anesthesia?&#x0D; Results: There were differences between the groups in terms of total pain score for example in group 1 there were 16 (53%) patients who did not make any movement during rocuronium injection while there were 22 (73%) patients in group 2.There was significant difference in injection rocuronium bromide pain between group 1: dexkethoprofen group, Group 2: control group in terms of the answer to the second question. Patients felt less pain than the control group. In the second question, 16% in group 2 stated that they felt pain, while this rate was observed as 3% in group 1.&#x0D; Conclusion: The effect of cox inhibitors on rocuronium pain was seen in our study but control group is also effective in reducing pain in vascular width.

Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium: An Age-Stratified Study.

Rocuronium intravenous pain is common in induction of general anesthesia. The aim of our study was to determine the median effective dose (ED50) of prophylactic intravenous remifentanil for the prevention of rocuronium injection pain and to explore the effect of age on the ED50. Eighty-nine adult patients undergoing elective general anesthesia, ASA I or II, regardless of gender or weight, were stratified according to age: group R1 18-44years, group R2 45-59years, and group R3 60-80years. The initial dose of prophylactic remifentanil before rocuronium injection was set at 1μg/kg lean body weight (LBW). The remifentanil doses were adjusted according to the degree of injection pain using the Dixon sequential method, with a ratio of 1.1 between adjacent doses. Injection pain was graded, and the occurrence of injection pain and adverse reactions were recorded. The ED50 and 95% confidence intervals (CIs) of remifentanil were calculated using the Dixon-Massey formula. Patients were asked whether they recalled feeling any injection pain in the post-anesthesia care unit (PACU). The ED50 (95% CIs) of prophylactic remifentanil for the prevention of rocuronium injection pain were 1.266μg/kg (1.186-1.351μg/kg), 1.188μg/kg (1.065-1.324μg/kg), and 1.070μg/kg (1.014-1.129μg/kg) LBW in group R1, group R2, and group R3, respectively. No adverse reactions to remifentanil occurred in any group. In PACU, 84.6, 86.7, and 85.7% of patients who experienced injection pain had memories of the pain in group R1, group R2, and group R3, respectively. Prophylactic intravenous remifentanil can prevent rocuronium injection pain, and its ED50 decreases with age, with 1.266μg/kg (18-44years), 1.188μg/kg (45-59years), and 1.070μg/kg LBW (60-80years), respectively. ClinicalTrials.gov: NCT05217238 (registration date 18 Dec 2021).

Rocuronium with sugammadex as a rescue reversal agent to solve conflicting recommendations for thyroid or parathyroid surgery. A prospective study

IntroductionFor thyroid or parathyroid surgery, there is a challenge to select a muscle relaxant agent allowing a good quality for tracheal intubation without any residual effect at the time of intraoperative neural monitoring. Patients and methodsIn this monocentric study, non-morbidly obese adult patients without risk factors for difficult tracheal intubation who underwent thyroid or parathyroid surgery with intraoperative neural monitoring were prospectively included. After rocuronium injection (0.5 mg.kg−1) during propofol-sufentanil induction, intubation conditions were evaluated using the Copenhagen score. The surgeon positioned the electrodes NIM® and tested the vagal nerve before recurrent nerve dissection. The signal was considered positive when the wave amplitude exceeded 100 μV. If not, sugammadex (2 mg.kg−1) was administered. The dissection began when the signal was positive. ResultsFrom January 2022 to June 2022, 48 out of 50 patients, 39 (81%) female, met inclusion criteria and were prospectively recruited in the study (two patients had predictable difficult intubation criteria). Intubation conditions were clinically acceptable for 46/48 (96%) of patients. The time delay from rocuronium injection to vagal stimulation was 43 min (mean) +/− 11 (SD). The vagal stimulation was positive in 45 patients (94%). In the 3 remaining patients, sugammadex successfully reversed residual curarization and allowed positive vagal stimulation. DiscussionThis prospective study shows that the use of 0.5 mg.kg−1 rocuronium with sugammadex as a rescue reversal agent allows good quality and safety for intubation conditions and intraoperative neural monitoring in patients scheduled for thyroid or parathyroid surgery.

Investigation of proarrhythmic effect of high sugammadex doses: an experimental animal study

BackgroundStudies on higher doses of sugammadex effect on QT interval and leading arrhythmia have been limited. In this study, we aimed to investigate possible proarrhythmic effect of higher doses of sugammadex in conditions that required urgent reversal of neuromuscular blockade during general anesthesia in an experimental animal model.MethodsIt was experimental animal study. Total of 15 male New Zealand rabbits were randomly divided into three groups for low (4 mg/kg, n = 5), moderate (16 mg/kg, n = 5), and high dose of sugammadex (32 mg/kg, n = 5). All rabbits were premedicated by intramuscular ketamine 10 mg/kg, and general anesthesia was inducted by intravenous injection of 2 mg/kg of a propofol, 1 mcg/kg fentanyl, and 0.6 mg/kg rocuronium injection. Airway was provided by V-gel rabbit and connected to anesthetic device and ventilated at about 40 cycle/min and 10 ml/kg; oxygen 50% plus air 50% mixture was used with 1 MAC isoflurane to maintain anesthesia. Electrocardiographic monitorization and arterial cannulation were provided to follow-up mean arterial pressure and for arterial blood gas analyses. Intravenous sugammadex in three different doses were injected at 25th min of induction. After observing adequate respiration of all rabbits, V-gel rabbit was removed. Parameters and ECG recordings were taken basal value before induction and at the 5th, 10th, 20th, 25th, 30th, and 40th min to measure corrected QT intervals and were stored on digital media. QT interval was calculated as the time from the beginning of the Q wave to the end of the T wave. Corrected QT interval was calculated according to the Bazett’s formula. Possible adverse effects were observed and recorded.ResultsIn all three groups, there was no significant statistical difference in mean arterial blood gases parameters, arterial pressures, heart rates, and Bazett QTc values, and no serious arrhythmia was recorded.ConclusionWe found in animal study that low, moderate, and high doses of sugammadex did not significantly altered corrected QT intervals and did not cause any significant arrhythmia.

Validity and Tolerability of Awake Calibration of an Accelerometer Neuromuscular Monitor.

Validity and Tolerability of Awake Calibration of an Accelerometer Neuromuscular Monitor.

Reversal of rocuronium-induced intense neuromuscular blockade by sugammadex in Korean children: A pharmacokinetic and pharmacodynamic analysis.

Sugammadex, a selective antagonist of steroidal non-depolarizing neuromuscular blocking agents, has been used in children in limited circumstances. However, neither pharmacokinetics (PKs) nor recovery profile of sugammadex for intense neuromuscular blockade reversal in children have been reported. This prospective study aimed to obtain a PK model of sugammadex and evaluate its efficacy and safety for intense neuromuscular blockade reversal in children. Forty children (age, 2-17 years) who underwent surgery that required early neuromuscular blockade reversal were enrolled. After neuromuscular blockade with 1mg∙kg-1 of rocuronium, sugammadex (2, 4, and 8mg∙kg-1 ) or a conventional dose of neostigmine (0.03 mg∙kg-1 ) was administered randomly after confirmation of zero post-tetanic count. The plasma concentrations of rocuronium and sugammadex were measured 2min after rocuronium injection; immediately before, 2, 5, 15, 60, 120, 240, and 480 min after the study drug injection. Response to train-of-four stimulation was continuously recorded. Noncompartmental analysis and population PK modeling were performed. For pharmacodynamics, the recovery profile was measured. Three-compartment PK model was established for sugammadex. The median (interquartile range [IQR]) time from injection of 8mg∙kg-1 of sugammadex to recovery of T4 /T1 greater than or equal to 0.9 at train-of-four stimulation was 1.1 (IQR: 0.88-1.8) min. No adverse events related to sugammadex were observed. We present a PK analysis of sugammadex for rocuronium-induced intense neuromuscular blockade reversal in children with its recovery profile. The time to recover T4 /T1 greater than or equal to 0.9 at train-of-four stimulation with 8mg∙kg-1 of sugammadex was less than 3min and comparable to that in adults.

Transcutaneous electric acupoint stimulation reduces rocuronium injection-related pain: a prospective randomized controlled study.

Various approaches have been suggested to reduce the pain and discomfort associated with rocuronium injection. This randomized controlled trial aimed at exploring the effectiveness of transcutaneous electrical acupoint stimulation (TEAS), a non-invasive modality to reduce the pain associated with rocuronium injection. 60 patients undergoing elective general anesthesia were recruited and randomly allocated to the TEAS or placebo TEAS (no electrical output) groups. TEAS consisted of 30 min of stimulation at a frequency of 2/100 Hz and an intensity of 6-9 mA on Hegu (LI4) and Neiguan (PC6) before anesthesia induction. A blinded observer evaluated the pain using a 4-point pain scale. The overall incidence of rocuronium injection-related pain was significantly lower in the TEAS group than that in the placebo TEAS group (40% and 86.7%, respectively). The incidence of no or mild pain was significantly higher in the TEAS group (100%, p<0,001) group than that in the placebo TEAS group (50%). Pretreatment with TEAS effectively reduced the frequency and severity of pain associated with rocuronium injection.

Propofol ve Rokuronyum Enjeksiyon Ağrısı İçin Vibrasyon Anestezisi

ABSTRACT Objective: Despite numerous strategies for preventing or alleviating pain associated with propofol and rocuronium injections, it remains common and distressing for patients. Application of vibration is an effective method of reducing pain during facial cosmetic injections and some venipuncture procedures. But it has been studied in limited trials for the context of propofol or rocuronium injection pain. This randomized study aims to evaluate the effect of vibration anesthesia on the incidence and severity of propofol and rocuronium injection pain. Methods: Fifty-one patients who underwent elective gynecologic operations under general anesthesia, were randomized, into two groups. On the dorsal side of the hand, a 20 G intravenous cannula was inserted. In Group V (n=25), propofol and rocuronium was administered following 1 minute of pre-treatment with the vibration device on the intravenous catheter trace. In Group C (n=26) vibration was not applied before drug administration. Propofol pain was recorded according to McCrirrick and Hunter scale and rocuronium injection pain response was evaluated with a four-point scale. Results: The number of patients who experienced propofol injection pain, in the vibration group was significantly lower than in the control group (p=0.007). The percentage of pain free patients in Group V was 88%, whereas 46% in Group C. The incidence of withdrawal movements associated with rocuronium injection pain was also significantly lower in Group V (p=0.043). Percentage of pain free patients in Group V was 28% whereas 3.8% in Group C. Conclusion: Vibration anesthesia before propofol and rocuronium injection significantly reduced the injection pain. Keywords: Injection pain, propofol, rocuronium, vibration

Post-General Anesthesia Angioedema After General Anesthesia

&lt;strong&gt;Background&lt;/strong&gt;: General anesthesia includes the administration of avariety medicines to patient/in/ fairly short/period. Numerous negative consequences can occur because of reaction from the drugs given, one example is anaphylaxis that may lead to death if not been recognized and handled quickly &amp;amp; promptly.&lt;p&gt;&lt;strong&gt;Case Illustration:&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;A sixty-seven years old male patient 152 cm 65 kg with multiple cholecystitis and obstructive jaundice, who was scheduled to undergo laparoscopic cholecystectomy. Patient had no records of allergy to medication and food. Family has no records to hypersensitive reactions or angioedema. At initial evaluation, blood pressure was 190/90 mmHg and hemoglobin 10,4 g/dL while the rest parameter was within normal limits. We given propofol and rocuronium to induce relaxation and facilitate intubation in surgery. Approximately 90 minutes after rocuronium injection, patient evolved angioedema across the face/area, tongue, and floor of the mouth. Patient also complained of not being able to talk. Soon after that, we give 10 mg of dexamethasone and 100 mg hydrocortisone to the patient. Within 60 minutes after hydrocortisone administration the patient shows/clinical improvement that marked by swelling began to decrease and the patient was able to speak again. Then we educate patient about angioedema and its alert.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Anaphylaxis is a type of hypersensitivity response that take place to a particular allergen and mostly self-limited, but 11% of hypersensitive reaction require airway intervention. Most of anesthetic medication such as thiopental sodium, propofol, muscle relaxants, and etomidate may induce anaphylactic reaction during anesthesia induction. Discontinuation of underlying agent and airway control may prevent mortality and morbidity.&lt;/p&gt;

Influence of the amount of skeletal muscle mass on rocuronium-induced neuromuscular block

ObjectiveTo evaluate the effects of skeletal muscle mass on the rocuronium-induced neuromuscular block. DesignA prospective, double-blinded, observational study. SettingA tertiary care university hospital. PopulationOne hundred one patients aged 18–65 years who were scheduled to undergo major surgery lasting more than 1 h under general anaesthesia. MethodsAll participants underwent body composition analysis before anaesthesia and were allocated into two groups; the muscular and non-muscular group, according to skeletal muscle mass. During anaesthesia induction, rocuronium 1.0 mg kg−1 of total body weight was injected followed by neuromuscular monitoring using train-of-four stimulation every 15 s. Main outcome measuresThe onset time of rocuronium included the elapsed time from the rocuronium injection until 95% depression of first twitch (T1) and the time to no response to TOF stimulation. The duration was evaluated as the elapsed time from the rocuronium injection to 25% recovery of the final T1 (TDUR25), and the time to the reappearance of T1 (TTOF1) and T4 (TTOF4). These pharmacologic data were compared between two groups. ResultsThere was no significant difference in the onset time of rocuronium between the two groups. However, TDUR25 (min) was significantly shorter in the muscular group than in the non-muscular group (p = 0.035 and p = 0.014 in males and females, respectively). TTOF1 and TTOF4 were also shorter in the muscular group than in the non-muscular group. ConclusionsTotal body weight-based dosing of rocuronium might prolong the neuromuscular relaxation effect in patients with a small amount of skeletal muscle.

A modified TOF-ratio to assess rocuronium-induced neuromuscular block: a comparison with the usual TOF-ratio

BackgroundThe TOFscan is an acceleromyographic neuromuscular monitor that calculates and displays two measurements: first, a train-of-four (TOF) ratio, or ratio of the fourth twitch in the TOF-sequence, T4, and the first twitch, T1 (T4/T1). In addition, a second, modified ratio is displayed (T4/Tr), which refers to the ratio between T4 and a reference twitch (Tr), calculated as the mean value of the four twitches in a TOF-sequence [Tr = (T1 + T2 + T3 + T4)/4]. T4/Tr is calculated before establishment of neuromuscular block. MethodsThis prospective observational study included 35 adult patients. NMB induced by a rocuronium bolus of 0.6 mg/kg was continuously monitored at the adductor pollicis with the TOFscan and both TOF-ratios were simultaneously assessed. Primary outcome was the comparison of recovery to a TOF-ratio ≥ 0.9 calculated as T4/T1 and T4/Tr. ResultsThe first value of the T4/T1 ≥ 90% was 90.9 (1.1) % and the simultaneously calculated T4/Tr was 69.6 (9.3) %, P < 0.001. The first value of the T4/Tr ≥ 90% was 90.5 (1.1) %, the simultaneously T4/T1 was 97.3 (2.5) %, P < 0.001. Time from injection of rocuronium to a TOF-ratio ≥ 90% was 56.2 ± 17.1 min for the T4/T1 and 65.3 ± 19.3 min for the T4/Tr, P < 0.001. During onset, a TOF ratio ≤ 20% was reached 145.5 (50.5) s after rocuronium when considering T4/T1, and 114.5 (45) s with the T4/Tr, P < 0.001. ConclusionThe present study shows the limitations of the usually determined acceleromyographic TOF ratio (T4/T1) in determining adequate neuromuscular recovery. The T4/T1 ratio significantly overestimates recovery compared with the T4/Tr ratio. Clinical decisions of adequate neuromuscular recovery based on the new T4/Tr ratio may reduce the incidence of residual paralysis and improve patient safety.

Time interval between alfentanil and rocuronium administration necessary to prevent rocuronium-induced withdrawal movement

BackgroundWe aimed to determine the time interval between alfentanil and rocuronium administration, at a 50% probability of preventing pain-induced withdrawal movement from rocuronium injection (TimeAR50).MethodsA total of 64 patients scheduled for general anesthesia were enrolled in this study (33 men and 31 women). Anesthesia was induced with target-controlled infusion of propofol, at an effect-site target concentration of 3 μg/mL. Then, alfentanil 15 μg/kg was injected for 30 s. After 60 s, rocuronium 0.6 mg/kg was administered to the first patient. The Dixon’s up-and-down method was used to determine the time interval for each subsequent patient (interval of 5 s). Mean arterial pressure (MAP) and heart rate (HR) were recorded at three time points: T0, pre-induction; T1, before rocuronium injection; and T2, 1 min after rocuronium injection.ResultsThe TimeAR50 ± standard deviation (SD) was 5.6 ± 3.7 s and 21.9 ± 5.6 s in the male and female patients, respectively. Based on the probit regression, the TimeAR50 was 4.7 s (95% confidence interval [CI], 1.2–7.6 s) and 20.3 s (95% CI, 7.7–26.1 s) in the male and female patients, respectively. The TimeAR95 was 10.6 s (95% CI, 7.7–25.3 s) and 35.0 s (95% CI, 28.1–95.5 s) in the male and female patients, respectively, with significantly higher values in females than in males (P < 0.001). Compared with the T0, MAP and HR decreased significantly at T1 and T2 in both groups.ConclusionThe TimeAR50 required for preventing rocuronium-induced withdrawal movement were 4.7 s and 20.3 s in male and female patients, respectively.Trial registrationThis study was registered with the Chinese Clinical Trials Registry on April 7, 2021 (URL: http://www.chictr.org.cn. Registry number: ChiCTR2100045137) .

A comparison of Lidocaine and Ketamine for prevention withdrawal from injection of Rocuronium.

Aim : To make comparison of the effects of lidocaine and ketamine in preventing withdrawal moments linked with IV injection of rocuronium . Methods: About sixty candidates (ASA I &amp; II) were chosen for this case research and categorized into two groups via aid of random number table in such a manner that each group contained 30 individuals. Candidates belonging to group A were administered ketamine in the dosage of 0.5mg/kg that was diluted in 2ml whereas group B candidates were administered 2ml of 1% lidocaine. On the dorsum of the hand, 20 gauge cannula will be inserted intravenously and candidate will be administered midazolamin doage of 0.02mg/kg intravenously for five minutes before coming into in the Operation theatre. After arrival of candidate , non-invasive routine monitoring of the candidates will be carried out and free fluid flow fluid via cannula will be assured by gravity with aid of IV fluid as normal saline. At room temperature, the syringes will be placed. Administration of drugs will be carried out via the injection port of intravenously cannula with a free fluid flow intravenously. Results: In case of ketamine , the prevalence withdrawal movements was recorded as 43.3% and lidocaine as 40%. In case of both research groups, the mean withdrawal scores were similar (P value two tailed = 1.0 (&gt;0.05). Two candidates among these individuals i-e one from each groups depicted generalized response (3.3%). No noteworthy difference was recorded in case of lidocaine and ketamine for preventing withdrawal moments after administration of injection of rocuronium. Conclusion: Equal effectiveness of lidocaine 1% and Ketamine 0.5mg/kg 2ml (20mg) was recorded in deducing withdrawal moments after administration of injection of rocuronium intravenously . Keywords: Lidocaine, ketamine, withdrawal movements

Investigation of potential neuropharmacological activity of neostigmine-glycopyrrolate for intraoperative neural monitoring in thyroid surgery.

Intraoperative neuromonitoring (IONM) is frequently used in thyroid surgery to reduce recurrent laryngeal nerve injury. The use of neuromuscular blockade agent to facilitate tracheal intubation, is a common cause of IONM failure. We performed a retrospective analysis to assess the efficacy of neostigmine-glycopyrrolate as a neuromuscular blockade reversal agent for IONM during thyroid surgery. Rocuronium (0.6mg/kg) was administered for muscle relaxation. Neostigmine (2mg) and glycopyrrolate (0.4mg) were administered immediately after intubation. Cricothyroid muscle-twitch response upon external branch of superior laryngeal nerve stimulation and electromyography amplitudes of vagal and recurrent laryngeal nerves before (V1, R1) and after thyroid resection (V2, R2) were recorded. Fifty patients (23 males, 27 females) were included in the analysis. The diagnoses comprised 43 papillary thyroid carcinomas and seven benign diseases. The mean time between rocuronium injection and neostigmine-glycopyrrolate injection was 5.1 ± 1.2min, and the mean time from neostigmine-glycopyrrolate injection to successful cricothyroid muscle twitching upon external branch of superior laryngeal nerve stimulation was 21.0 ± 4.5min. All patients had V1 and R1 amplitudes of more than 500 μV each, with mean V1 and R1 amplitudes of 985.3 ± 471.6μV and 1177.2 ± 572.7μV, respectively. Neostigmine-glycopyrrolate was effectively used as a neuromuscular blockade reversal agent for IONM in thyroid surgeries without a significant increase in bucking events. Administration of neostigmine-glycopyrrolate immediately after intubation can be recommended for successful NMB reversal to facilitate IONM during thyroid surgery.

Preoperative effects of magnesium sulfate on hemodynamics and muscle relaxation

Background/Aim: Although there are many studies on the effects of magnesium sulfate in the literature, there is no publication on the effects of low doses of magnesium sulfate, as we administered in our study. This prospective randomized study aimed to reveal that the use of low-dose magnesium sulfate (MgSO4) shortens the onset time and prolongs the block duration of neuromuscular blockers (NMBs) without changing the hemodynamics in patients monitored using the train-of-four (TOF) ratio. Methods: This is a prospective randomized study. A total of 60 cases aged between 18–65 years with American Society of Anesthesiologists classifications I–II who were scheduled for elective open cholecystectomy were randomly divided into 3 groups. Notably, 15 minutes before the anesthesia induction, 25 mg/kg MgSO4 in intravenous 0.9% saline (total volume, 100 mL) was administered to the MgSO4 group (MS group), 0.03 mg/kg midazolam was administered to the midazolam group (MD group), and the same volume of 0.9% saline solution was administered to the control group (PSS group). Nerve-muscle conduction monitoring was performed using TOF-Watch® SX (Organon, Ireland) and anesthesia depth was monitored with a BIS® monitor (A-2000; Aspect Medical Systems, USA). Results: NMB onset times were 83.95 (26.8), 111.15 (28.12), and 163.7 (34.16) seconds (P=0.001) in the MS, MD, and PSS groups, respectively. The times until additional rocuronium requirement after the intubation dose were 60.1 (4.19), 50.8 (4.99), and 38.25 (7.27) minutes in the MS, MD, and PSS groups, respectively, which was significantly longer in the MS group compared to the other groups (P 95% was longer in the MS group than in the other groups. No difference was found between the groups in terms of hemodynamic data. Conclusion: Low-dose MgSO4 administration before rocuronium injection significantly reduces neuromuscular agent consumption without altering hemodynamics and causing a residual neuromuscular block.